Press Releases

Date Title and Summary View
Toggle Summary T-SPOT®TB is first IGRA to be Approved for Sale in Taiwan
T-SPOT ® TB is first IGRA to be Approved for Sale in Taiwan 18 th December 2009 – Oxford Immunotec, Ltd., the world’s leading manufacturer and marketer of T Cell based diagnostic tests announced today that T-SPOT. TB has become the first Interferon Gamma Release Assay (or
View HTML
Toggle Summary Oxford Immunotec Announces Board Changes
Oxford Immunotec Announces Board Changes Oxford, UK 27th October 2008 - Oxford Immunotec, Ltd., the world's leading manufacturer and marketer of T Cell based diagnostic tests announced today that Lawrence Kinet has retired as Chairman of the Company to focus on his new role as CEO of LMA
View HTML
Toggle Summary T-SPOT®.TB Gains FDA Premarket Approval
T-SPOT ® .TB Gains FDA Premarket Approval Oxford, UK [Marlborough, MA]; 01 August 2008 - Oxford Immunotec, the global T-cell diagnostic company, today announced that the U.S. Food and Drug Administration (FDA) has approved a premarket approval application (PMA) for the T-SPOT ® . TB test.
View HTML
Toggle Summary Study Results Confirm T-SPOT®.TB Performance is not Affected by Low CD4 Count in HIV Infected Subjects
Oxford, UK; 23 May 2008 - Oxford Immunotec, the T cell measurement company, today announced the publication of a recent study, demonstrating the efficacy of using T-SPOT. TB to identify TB infection in HIV infected subjects. In this study reported in Clinical and Experimental Immunology Clark et al
View HTML
Toggle Summary Study Results Demonstrate Ability of T-SPOT®.TB to Monitor Declining Response in Subjects Receiving Anti-TB Treatment
Study Results Demonstrate Ability of T-SPOT ® .TB to Monitor Declining Response in Subjects Receiving Anti-TB Treatment Oxford, UK; 20 February 2008 - Oxford Immunotec Ltd., the T cell measurement company, today announced the publication of a recent study demonstrating a decline in the
View HTML
Toggle Summary Study Results Demonstrate Accuracy of T-SPOT®.TB in Contact Tracing
Study Results Demonstrate Accuracy of T-SPOT ® .TB in Contact Tracing Oxford, UK; 20 February 2008 - Oxford Immunotec Ltd, the T cell measurement company, today announced the publication of a recent study demonstrating a decline in the positivity of its T-SPOT.
View HTML
Toggle Summary Oxford Immunotec Completes $40M Financing
Oxford Immunotec Completes $40M Financing T cell diagnostics company secures European diagnostics sector's largest funding round since 2006* Oxford, UK; 29th October 2007 - Oxford Immunotec Ltd., the fully integrated T cell diagnostics company, announced today that it has closed a financing round
View HTML
Toggle Summary Study Results Confirm T-SPOT®.TB is Cost-Effective in TB Control Programmes
Study Results Confirm T-SPOT ® .TB is Cost-Effective in TB Control Programmes Oxford, UK; 9th October 2007 - Oxford Immunotec Ltd., the T cell measurement company, today announced the publication of a recent study demonstrating that T-SPOT. TB is cost-effective when used in contact tracing
View HTML
Toggle Summary Study Results Suggest the Utility of T-SPOT®.TB in Monitoring Treatment for Latent TB Infection (LTBI)
Study Results Suggest the Utility of T-SPOT ® .TB in Monitoring Treatment for Latent TB Infection (LTBI) Oxford, UK; 10th September 2007 - Oxford Immunotec Ltd., the T cell measurement company, today announced the publication of a recent study demonstrating the potential use of T-SPOT.
View HTML
Toggle Summary Report Highlights the Reliability of T-SPOT®.TB Following Administration of the Tuberculin Skin Test
Report Highlights the Reliability of T-SPOT ® .TB Following Administration of the Tuberculin Skin Test Oxford, UK; 10th August 2007 - Oxford Immunotec Ltd., the T cell measurement company, today announced the report of a recent study demonstrating the reliability of T-SPOT.
View HTML